2008
Sommerfelt MA and Sørensen B.
Prospects for HIV-1 therapeutic immunisation and vaccination:
the potential contribution of peptide immunogens.
Expert Opin on Biol Ther June2008 8(6):745-57
Abstract



2007
Kran A-MB, Jonassen TØ, Løvgården G, Sommerfelt MA, Sørensen B, Kvale D
Low frequencies of escape mutations after 15 months viraemia following efficient therapeutic
immunisation using conserved HIV p24-like peptides
Keystone Symposia 2007, Canada
Abstract



2006
Nyhus J, Kran A-MB, Sommerfelt MA, Baksaas I, Sørensen B, Kvale D
Multiple antigen concentrations in delayed-type hyper- sensitivity (DTH) and response diversity
during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).
Vaccine 2006; 24: 1543-50,
Abstract


Kvale D, Kran AMB, Sommerfelt MA, Nyhus J, Baksaas I, Sørensen B. (2006) Comparable
Immunogenicity between patients on or off combination antiretroviral therapy (CART) after immuni-
zationwith a novel therapeutic peptide-based immunotheraoy candidate targeting dendritic cells (DC). AIDS Vaccine 06 conference. Amsterdam. Abstract Nr. P12-03.
Abstract


Sommerfelt MA, Wit F, Nyhus J, Kran AMB, Baksaas I, Lange J, Sørensen B, Kvale D. (2006)
Comparing CD4+ T-cell decline during treatment interruption in HIV-1-infected patients who did
or did not receive the candidate immunotherapy Vacc-4x. XVI AIDS International Conference, Toronto. Abstract Nr. MOAX0404.
Abstract


Kran A-MB, Sørensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
AIDS 2006; 20(4): 627-30
Abstract



2005
Kran A-MB, Sommerfelt MA, Sørensen B, Nyhus J, Baksaas I, Bruun J, Kvale D. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Vaccine 2005; 23(31): 4011-5
Abstract


Kvale D, Kran A-MB, Sommerfelt MA, Nyhus J, Baksaas I, Bruun J, Sorensen B.
Divergent in vitro and in vivo correlates of HIVspecific T-cell responses during onset of HIV viraemia.
AIDS 2005, 19: 563–567
Abstract



2004
Kran A-MB, Sørensen B, Nyhus J, Sommerfelt MA, Baksaas I, Bruun J, Kvale D. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 Immunotherapy Candidate (Vacc-4x).
AIDS 2004; 18(14): 1875-1883
Abstract


Sommerfelt MA, Nyhus J, Sorensen B.
Novel peptide-based HIV-1 immunotherapy.
Expert Opin Biol Ther 2004; 4(3): 349-361
Abstract



2002
Asjo B, Stavang H, Sørensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic
HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
AIDS Res Hum Retroviruses 2002; 18(18): 1357-65.
Abstract